# Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

> **NCT04405349** · PHASE2 · COMPLETED · sponsor: **Nykode Therapeutics ASA** · enrollment: 52 (actual)

## Conditions studied

- Cervical Cancer
- Cervix Cancer

## Interventions

- **BIOLOGICAL:** VB10.16
- **BIOLOGICAL:** Atezolizumab

## Key facts

- **NCT ID:** NCT04405349
- **Lead sponsor:** Nykode Therapeutics ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2023-11-24
- **Final completion:** 2023-11-24
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405349, "Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04405349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*